Articles by Katie Anderson

  1. Bristol Myers Squibb Forms Immunology Company With Finance Partner 8/5/2025

    The NewCo pipeline will start with three clinical-stage and two phase 1-ready investigational medicines that each target mechanisms in autoimmune diseases.

  2. George Tidmarsh Named CDER Director 7/24/2025

    Tidmarsh has over 30 years of experience in biotechnology, clinical medicine, and regulatory science and has authored 143 scientific publications and patents.

  3. Sanofi Expands Immunology Portfolio With Blueprint Acquisition 7/24/2025

    Sanofi expanded its portfolio in immunology with the completed acquisition of Blueprint Medicines Corporation.

  4. The 3 Big Barriers To AMT Implementation 7/18/2025

    Advanced manufacturing technologies (AMTs) can not only lower costs but also improve the quality and consistency of both API and final dosage manufacturing in pharmaceuticals, so why are they not more widely implemented?

  5. FDA Publishes 200+ CRLs For Increased Transparency 7/16/2025

    The letters were made available to increase transparency and help sponsors reduce similar mistakes in the future.

  6. Can AMTs Make U.S. Pharmaceuticals Faster, Better, Stronger? 7/11/2025

    As the pharmaceutical industry prepares for impending tariffs and invests in domestic manufacturing, advanced manufacturing technologies present a viable opportunity to modernize systems for improved efficiency, consistent quality and potentially lower costs.

  7. Researchers Switch Up Paracetamol Production With Eco Method 7/2/2025

    Scientists at the University of Edinburgh’s Wallace Lab developed a method to produce paracetamol that can reduce environmental pollution and the industry’s reliance on fossil fuels

  8. FDA Addresses U.S. Health Crisis With Voucher Program 7/2/2025

    FDA Commissioner Marty Makary, M.D., M.P.H., tapped into his oncologist experience to launch a new FDA program designed to fast-track the time it takes for important drugs to receive approval and get to patients.

  9. Lab Oversupply Is Pushing Leasing, Rent and Relocation Down 7/1/2025

    The landscape of the U.S. pharmaceutical lab market is changing, according to JLL’s U.S. Life Sciences Property Report. In addition to the effort to bring pharma manufacturing back to the U.S. ahead of looming tariffs, an oversupply of space and lower tenant demand in large biopharma markets is dropping leasing rates, rent costs and lease duration, among other changes.

  10. CDER's Director Set To Retire Amid FDA Leadership Shuffle 7/1/2025

    Jacqueline Corrigan-Curay, M.D., J.D., announced plans to retire from her position as acting director of CDER, calling the decision "incredibly challenging." Corrigan-Curay is not alone in her decision to leave the FDA, with a number of leaders exiting the agency since January.